|Awarded On||February 16, 2022|
|Title||Imaging Metabolic Reprogramming in Prostate Cancer|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Federica Pisaneschi|
Patients with advanced prostate cancer (PCa) receive anti-androgens (Enzalutamide) as the first line of treatment. Unfortunately, many patients develop resistance, and the disease relapses with aggressive histology and metastatic castrate-resistant (mCRPC) phenotype. Treatment options for mCRPC patients are limited and continue to pose a significant oncological challenge.
There is growing recognition that alterations in cell metabolism and reprogramming of metabolic pathways are key drivers of PCa aggressiveness, progression and eventual resistance to therapy. We propose to develop metabolic imaging to target treatment strategies of different metabolic sub-types of PCa. Two dysregulated meta...